^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug Class:PTPN11 inhibitor +
    ERK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-NCI-EORTC 2022
    Title:

    A combination vertical inhibition approach with inhibitors of SHP2 and ERK provides improved activity in KRAS-mutant pancreatic and colorectal cancer models

    Published date:
    10/12/2022
    Excerpt:
    Treatment with the combination more effectively inhibited the growth of KRAS-mutant xenograft tumors in vivo, such as KRASG12C-mutant Mia-PaCa2 xenografts, when compared to either single agent….These data support our hypothesis that the combination of SHP2 and ERK inhibitors enhances inhibition of cell growth over the single agents in KRAS-mutant PDAC and CRC cell lines.